Interestingly, FXR agonists compounds and drugs such as signalling biliary acids (e.g. obeticholc acid34) might therefore elicit a zonal therapeutic response, which may allow targeting of the pharmacodynamic effect to the pericentral disease location in NAFLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.